

# Request for proposal (RFP)



For a higher-order structure analyses of JJP-1212, an IgG4 $\kappa$  monoclonal antibody, to support the clinical phase of the drug development process

Project *“Development of first-in-class antibody therapy for treatment of the ultra-rare LABD indication as well as for pulmonary and autoimmune diseases with IgA mediated pathology, using Companion Diagnostics (CDx) patient stratification for treatment with the JJP-1212”*,  
financed by the Medical Research Agency (Poland)

*Number of RFP: 2312\_T01\_TSI\_01*

**JJP Biologics**  
Bobrowiecka 6,  
00-728, Warsaw,  
Poland

## Company and scientific background

JJP Biologics is a newly established Polish biotechnological company focused in the areas of autoimmune diseases and cancer.

Autoantibodies have been reported to be involved in the pathogenesis of many autoimmune and inflammatory disease indication. Especially autoantibodies from the IgA isotype are reported to correlate closely with disease severity. Moreover, IgA antibodies have highly potent effector function that promotes the IgA autoantibodies from just a biomarker to pathological effector molecule that drive the disease in autoantigen IgA positive patients.

First-into-Human indication is Linear IgA Bullous Disease (LABD) and these LABD patients have IgA autoantibodies and massive accumulation of activated neutrophils in the skin. These IgA autoantibodies in LABD are directed against collagen type XVII, which is an important adhesion molecule in the dermo-epidermal junction. Neutrophil (over) activation in LABD seems to be the direct result of CD89 triggering by IgA autoantibodies, which leads to skin damage and blister formation followed by skin damage.

## Lead molecule and status

The desired Product is a S228P-stabilized humanized Immunoglobulin G4 (IgG4) monoclonal antibody, which binds to CD89 (the IgA receptor or Fc $\alpha$ R) and antagonizes IgA-mediated stimulation expressed on human neutrophils, monocytes, macrophages, and eosinophils.

One of the components of JJP-1212' is higher-order structure analysis.

## Scope of Request for proposal

JJP Biologics will commission to the Company a higher order structure analyses. This analyses can be done by CD or FT-IR spectroscopy (both are equally acceptable).

1. Secondary structure determination by CD spectroscopy in the "far-UV" spectral region (190-250 nm)
  - Method establishment and feasibility
  - Sample analysis - 2 repetitions
2. Secondary structure determination by FTIR spectroscopy
  - Method establishment and feasibility
  - Sample analysis - 2 repetitions

### → Deliverables:

- Final report from analyses

### Requirements for the supplier or service provider

- It is required that the bidder has at least 1 year of experience in higher-order structure analyses.

### Schedule

- We expect the vendor to conduct an analyses in January 2024
- Report from analyses must be prepared **preferably by the end of January**, the maximum date accepted is 09.02.2024.

=> Information about availability of Vendor's time slots according to the given timeline should be included in the proposal.

### Criteria of choice

The decision to conclude any work order, regarding a project, as a result of this RFP process will be based on responses. The decision-making process will consider the ability of each service provider to fulfil JJPB's needs and requirements as outlined within this RFP.

Proposals will be assessed against the following criteria:

- **100%** - proposed total net price

The number of points will be calculated according to the formula:

$CN/CB \cdot 100$  points

where:

CN - among the responses meeting the RFP' requirements, the lowest net total price

CB - net total price of the examined offer

*The offer with the highest number of points will be considered the most advantageous.*

### **Deadline for the bid submission**

Deadline for submission of the offer is **03.01.2024**.

=> Proposal should be sent in a non-editable version (pdf)

### **Remuneration**

- Please provide a total price offer in Euros or Zloty\*.
- Total cost should cover all costs needed to complete the order.

*\* If bidders' prices are given in one currency, the prices indicated by bidders will be used for comparison. If the prices are given both in PLN and in Euro, the prices converted into PLN at the exchange rate on the last day of submitting offers will be used for price comparison.*

**\*\*\***

JJP reserves the right to terminate or cancel the proceedings if, due to an extraordinary change of circumstances, the fulfilment of the performance would be connected with undue hardship or would threaten one of the parties with a substantial loss. This also applies to the stage after the selection of the best offer.

### **Contact**

Questions regarding the inquiry as well as the offer, please send to [zapytaniabadania@jjpbiologics.com](mailto:zapytaniabadania@jjpbiologics.com)

=> Please submit RFP questions, if any, no later than 2 days before the deadline for submission of offers.